

Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 752 877 B1**

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
**05.07.2000 Bulletin 2000/27**

(51) Int.Cl.7: **A61K 38/11, A61K 9/20,  
A61K 9/22, A61K 9/52**

(21) Application number: **95914605.1**

(86) International application number:  
**PCT/SE95/00249**

(22) Date of filing: **09.03.1995**

(87) International publication number:  
**WO 95/25534 (28.09.1995 Gazette 1995/41)**

(54) **STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES**

**STABILISIERTE ZUSAMMENSETZUNG ZUR ORALEN VERABREICHUNG VON PEPTIDEN**  
**COMPOSITION STABILISEE POUR L'ADMINISTRATION DE PEPTIDES PAR VOIE ORALE**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GRIE IT LI LU MC NL  
PT SE**

• **AHLM-SÖDERBERG, Christina**  
**216 11 Malmö (SE)**

(30) Priority: **18.03.1994 SE 9400918**

(74) Representative:  
**Thiel, Christian, Dr. Dipl.-Chem. et al**  
**Schneiders & Behrendt**  
**Rechts- und Patentanwälte**  
**Huestrasse 23**  
**(Westfalenbankgebäude)**  
**44787 Bochum (DE)**

(43) Date of publication of application:  
**15.01.1997 Bulletin 1997/03**

(73) Proprietor: **FERRING B.V.**  
**2130 KC Hoofddorp (NL)**

(56) References cited:  
**WO-A-94/21286** **US-A- 4 910 021**

(72) Inventors:  
• **FJELLESTAD-PAULSEN, Anne**  
**75005 Paris (FR)**

**BEST AVAILABLE COPY**

**EP 0 752 877 B1**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## EP 0 752 877 B1

## Description

[0001] The present invention relates to pharmaceutical compositions in solid form for oral administration of small and medium size peptides, particularly vasopressin, oxytocin, and their analogues. The present invention also relates to a method for manufacture of a single dose of said composition for oral administration of small and medium-size peptides, particularly vasopressin, oxytocin, and their analogues.

[0002] The invention further relates to a method for administration of said composition to a patient.

## BACKGROUND

[0003] A number of medicines for treatment of a variety of diseases contain, as active principle, naturally occurring peptides or their synthetic analogues.

[0004] Because of the instability of small and medium size peptides, particularly vasopressin, oxytocin, and their analogues, in the environment of the gastrointestinal tract their uptake, when given as a medicine or for similar reasons, is still very unsatisfactory. Thus, better delivery systems for non-parenteral, particularly for oral, administration of peptides and their analogues are desirable, cf. Davies, S.: "Developing delivery systems for peptides and proteins", Scrip Magazine 1992, 34-38.

## OBJECTS OF THE INVENTION

[0005] It is an object of the present invention to provide a pharmaceutical composition of the kind known in the art and mentioned above which provides for better absorption of said small or medium-size peptides, particularly vasopressin, oxytocin, and their analogues.

[0006] It is another object of the present invention to provide a method of manufacture of a single dose of said pharmaceutical composition for oral administration of small and medium-size peptides, particularly vasopressin, oxytocin, and their analogues.

[0007] It is a further object of the invention to provide a method for administration of said composition to a patient.

[0008] Additional objects of the present invention will become evident by study of the detailed description of preferred embodiments of the invention.

## SUMMARY OF THE INVENTION

[0009] The above and other objects of the invention are provided by a pharmaceutical composition of the kind described above, said composition comprising a small and medium size peptide, particularly vasopressin, oxytocin, or an analog of vasopressin or oxytocin, an enteric coat, and a pharmaceutically acceptable carrier containing a buffering agent buffering at a pH of from 2 to 6, more preferred from 4 to 5.5, most preferred at about pH 5, said composition does not comprise a protease inhibitor. It is preferred for the peptide to be chosen from DDAVP (desmopressin), oxytocin, CAP (atosiban), and carbetocin. Particularly preferred is DDAVP. For full sequences of these peptides, see Table 1 at the end of the DETAILED DESCRIPTION section. Another group of peptides preferred for oral administration by incorporation into the composition according to the invention comprises GnRH-analogues (gonadotropin-releasing hormone analogues) such as gonadorelin and triptorelin.

[0010] It is preferred for the the pharmaceutically acceptable carrier to further comprise one or several agents selected from the group consisting of carbohydrates and modified carbohydrates and derivatives thereof, polyethylene and/or polypropylene glycol and derivatives thereof, inorganic fillers or lubricating agents, fatty acids and their esters and salts, preservatives and coating agents. Suitable pharmaceutical acceptable carriers comprise a wide variety of carriers for production of pharmaceutical formulations in tablet or capsule form, e.g. the carrier of the antidiuretic composition containing DDAVP disclosed in the European patent no. 163 723. Especially preferred are multiparticle systems, such as systems for administration in soft and hard gelatin capsules; preferred particle sizes for spheres containing peptide are below about 2 mm.

[0011] According to a preferred aspect of the invention the enteric coat is designed for release of its contents in the small intestine. It is particularly preferred for the particles contained in the tablets or capsules to be coated with an enteric coating for delayed release of their contents in the upper part of the small intestine. The enteric-coated spheres may also be contained in a tablet that readily disintegrates in the stomach or may be administered in suspended form in media that will not readily dissolve the enteric coating.

[0012] The enteric coat is soluble in gastric juice at a pH of about 5.0 or higher; particularly preferred is a pH of about 5.5 or higher. Enteric coatings that are not readily dissolvable in such fluids at a pH of about 6.5, however, will not permit substantial release of the ingredients of the composition according to the invention in the upper small intestine and, therefore, are not included; on the other hand, coatings that dissolve in gastric fluids at a pH substantially lower

## EP 0 752 877 B1

than 5,0 are also not included since they will release the ingredients in the stomach. Useful enteric coatings according to the invention comprise polymer having dissociable carboxylic groups, such as derivatives of cellulose, including hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate and cellulose acetate trimellitate and similar derivatives of cellulose and other carbohydrate polymers, as well as polyvinylacetate phthalates and similar partial esters of dibasic or tribasic carboxylic acids with polyvinylacetate and similar polymers carrying alcoholic hydroxyl groups. The enteric coating may also advantageously be prepared from mixtures of such polymers.

[0013] The peptide is preferably admixed with a carrier comprising a buffering agent and one or several agents selected from the group consisting of carbohydrates and modified carbohydrates and derivatives thereof, polyethylene and/or polypropylene glycol and derivatives thereof, organic and inorganic core, filler or lubricating materials, fatty acids, their esters and salts, preservatives, antioxidants, and coating agents. The buffering agent should be able to buffer at a pH from about 2 to about 6, more preferred from about 4 to 5,5, most preferred at about pH 5, i.e. to exert substantial buffer capacity within this range and preferably at about pH 5. The preferred pH-range according to the invention is a compromise between, at the one hand, maximizing stabilization effect and, on the other hand, protection of the intestinal wall against potential injury by low pH. Since the composition according to the invention is intended for preferred release in the upper part of the small intestine where, during their passage, the acidic contents of the stomach are neutralized by influx of Na<sup>+</sup>, buffering inhibits or delays an increase of pH exceeding the preferred range or, in other words, in the direction of the upper limit of the preferred range and exceeding that upper limit. The buffering agent thus forms a barrier for the natural neutralization of the stomach's content upon emptying into the small intestine through the pylorus. Preferred buffering agents are hydrogen and dihydrogen phosphates, such as sodium dihydrogen phosphate and mixtures of sodium dihydrogen phosphate with disodium hydrogen phosphate, calcium tetrahydrogen phosphate, citric acid and mixtures of citric acid and its monosodium salt, fumaric acid and its monosodium salt, adipic acid and its monosodium salt, tartaric acid and its sodium salt, ascorbic acid and its monosodium salt, glutamic acid, aspartic acid, betaine hydrochloride, hydrochlorides of amino acids, such as arginine monohydrochloride and glutamic acid hydrochloride, and saccharic acid. It is preferred for the buffering agent to comprise at least 10 % by weight, more preferred at least 25 % by weight, most preferred at least 40 % by weight of the composition according to the invention. A mixture of two or more buffering constituents can be used.

[0014] According to the invention there is also provided a method of manufacture of single doses of the composition according to the invention, said method comprising the following steps:

- mixing the peptide and a suitable carrier including a buffering agent buffering in the range from pH 2 to pH 6, more preferred from pH 4 to pH 5,5, most preferred at about pH 5,
- spheronizing the mixture for formation of spheres with a diameter smaller than about 2 mm,
- coating the spheres with an enteric coat which is readily soluble in gastric juice of pH 5.0 or higher but not readily soluble at substantially lower pH,
- filling the coated spheres in capsules or - incorporating them into tablets, said capsules or tablets being readily disintegrable in the stomach.

## DETAILED DESCRIPTION

[0015] The invention will now be described in greater detail by reference to degradation of DDAVP in gastric juice.

## Example 1

[0016] Human gastro-intestinal juice was obtained from healthy male volunteers who had been fasting for 8 h. A tube was introduced intranasally after local anaesthesia with xylocaine, and gastric juice was collected. Thereafter one standardized meal was given 1 h before sampling of duodenal and distal jejunum juice and another the next morning before the collection of distal ileal juice. After centrifugation the gastric and intestinal juices were frozen in aliquots of 1 ml and stored at - 20° C.

[0017] Degradation method. The peptide or peptide analog (10 µl of 10 mM peptide in 0.9 % aqueous NaCl) was added to 190 µl of undiluted juice at 37° C. Aliquots of 25 µl were withdrawn at intervals and mixed with 100 µl acetone to stop the reaction. After centrifugation for 10 min at 10,000 g, 10 µl of the supernatant was analyzed by reversed phase HPLC.

[0018] Determination of peptide degradation. Analysis was carried out in a Varian 5000 HPLC analyzer equipped with a UV-detector (220 nm). Column Bondapak TM C18 (3.9 x 300 mm), eluant MeOH/0.025 M NH<sub>4</sub>Ac (isocratic conditions), flow rate 1 ml/min.

[0019] Protein and pH determination. Protein: Bio-Rad protein assay. pH: Orion model SA720; pH-paper Merck (Darmstadt), range 4.0 - 7.0.

[0020] Results. DDAVP was found to be degraded (to about 50 % after 35 min) by both gastric and intestinal juices

## EP 0 752 877 B1

at pH 6.5. When the pH was adjusted to 4.0 DDAVP appeared to be essentially stable. Absent pH-adjustment, DDAVP proteolysis was found to be slower in jejunal or duodenal juice than in ileal juice.

## Example 2

## Experiments in rat.

[0021] SPD male rats weighing about 300 g were anaesthetized with 15 mg/kg with thiobutabarbital sodium (Inactin™, Byk Gulden, Germany). After opening the abdominal cavity a cut about 3 mm in length was made in the small intestine about 15 mm distally from the pylorus. Through this cut a gelatin capsule was inserted into the small intestine, the capsule containing 0.10 ml of peptide solution containing 2.0 mg peptide per ml of aqueous citrate buffer solution (pH about 2.5, prepared by mixing 22.3 ml of 1 M citric acid, 2.7 ml of 2.0 M sodium phosphate and 25 ml of water). Time record was started, the intestine sutured and the abdominal cavity closed. Blood samples were drawn at predetermined intervals from a catheter in the carotid artery. Peptide content determination was by RIA. Results shown in Fig. 1 demonstrate the stabilizing effect of the composition according to the invention over the corresponding non-buffered preparation (Fig. 2) which was prepared by dissolving a corresponding amount of DDAVP in 0.9 % of saline. The results for the four rats used in each experiment are shown in separate curves.

## Example 3

[0022] Tablets according to the invention containing selected amounts of DDAVP and a pH-buffering agent (25 % by weight of calcium tetrahydrogen phosphate and 3 % by weight of disodium hydrogen phosphate) can be manufactured by slight modification of the method disclosed in EP-A-0 163 723. These tablets can be spray-coated with useful enteric coatings such as described by Agyilrah, G. A. and Banker, G. S. in Polymers for controlled drug delivery, Tarcha, P. J., Ed., CRC Press, Boca Raton 1991, p. 39-66.

## Example 4

[0023] Hard gelatin capsules containing a particulate enteric-coated DDAVP formulation according to the invention can be obtained in the following way. Solid core particles (100 g) prepared according to EP-A2-0 366 277 (example 3) are coated with 760 ml of an aqueous solution containing 20.0 mg DDAVP acetate, and these coated particles are spray-coated in a Spheronizer® fluid-bed coater with a methanol - methylene chloride 1 : 1 coating solution containing (by weight) 10 % of polyvinyl acetate phthalate (PVAP; TD-17, Colorcon Inc., West Point, PA), 0.7 of glyceryl triacetate and 1 % of stearic acid, and dried. Hard gelatin capsules are filled with these enteric-coated particles (250 mg/capsule).

# EP 0 752 877 B1

## Table 1

Peptide or peptide analog	Sequence
CAP (atosiban)	Mpa-D-Tyr (Et) -Ile-Thr-Asn-Cys-Pro-Orn-GlyNH <sub>2</sub>
carbetocin	Bua-Tyr (Me) -Ile-Gln-Asn-Cys-Pro-Leu-GlyNH <sub>2</sub>
DDAVP (desmopressin)	Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-GlyNH <sub>2</sub>
oxytocin	Cys-Tyr-Ile-Asn-Cys-Pro-Leu-GlyNH <sub>2</sub>

## Claims

1. A pharmaceutical composition in solid form for oral administration comprising a peptide chosen from the group consisting of vasopressin, oxytocin or an analogue of vasopressin or oxytocin, an enteric coat readily soluble in gastric juice at a pH of about 6.5 or lower, preferably at about pH 5.5, but not readily soluble at a pH substantially lower than 5.0, said coat selected from polymers having dissociable carboxyl groups, and a pharmaceutically acceptable carrier containing a buffering agent buffering at a pH of from 2 to 6, provided that the composition does not comprise a protease inhibitor.
2. The composition of claim 1, wherein the peptide is chosen from the group consisting of DDAVP (desmopressin), oxytocin, CAP (atosiban), and carbetocin.
3. The composition of claim 2, wherein the peptide is DDAVP.
4. Composition according to claim 1, wherein the pharmaceutically acceptable carrier further comprises one or several agents selected from the group consisting of carbohydrates and modified carbohydrates and derivatives thereof, polyethylene and/or polypropylene glycol and derivatives thereof, inorganic fillers or lubricating agents, fatty acids and their esters and salts, preservatives and coating agents.
5. Composition according to claim 1, comprising an enteric coat for release of its contents in the upper part of the small intestine.
6. Composition according to any preceding claim, wherein the enteric coat is selected from cellulose derivatives, including hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate and similar derivatives of cellulose and other carbohydrate polymers, phthalates of vinyl acetate and similar partial esters of dibasic or tribasic carboxylic acids with polyvinyl acetate and similar, polymers carrying alcoholic hydroxyl groups or a mixture of such polymers.

## EP 0 752 877 B1

7. Method for manufacture of single doses of the composition according to any of claims 1 to 6, comprising the following steps:

- mixing the peptide and a suitable carrier including a buffering agent buffering in the range from pH 2 to pH 6, more preferred from pH 4 to pH 5,5, most preferred at about pH 5,
- spheronizing the mixture for formation of spheres with a diameter smaller than about 2 mm,
- coating the spheres with an enteric coat which is readily soluble in gastric juice of pH 5.0 or higher but not readily soluble at a substantially lower pH,
- filling the coated spheres in capsules or incorporating them into tablets, said capsules or tablets being readily disintegrable in the stomach.

### Patentansprüche

1. Pharmazeutisches Mittel in fester Form zur oralen Verabreichung, umfassend ein Peptid, ausgewählt aus der Gruppe, bestehend aus Vasopressin, Oxytocin oder einem Analogen von Vasopressin oder Oxytocin, einen enteralen Überzug, der in Magensaft bei einem pH von etwa 6,5 oder darunter, vorzugsweise bei einem pH von etwa 5,5, leicht löslich ist, aber bei einem pH wesentlich unter 5,0 nicht leicht löslich ist, wobei der Überzug ausgewählt ist aus Polymeren, mit abspaltbaren Carboxylgruppen, und einen pharmazeutisch annehmbaren Träger, der ein Puffermittel enthält, das bei einem pH von 2 bis 6 puffert, mit der Maßgabe, daß das Mittel keinen Proteaseinhibitor umfaßt.
2. Mittel nach Anspruch 1, wobei das Peptid ausgewählt ist aus der Gruppe, bestehend aus DDAVP (Desmopressin), Oxytocin, CAP (Atosiban) und Carbetocin.
3. Mittel nach Anspruch 2, wobei das Peptid DDAVP ist.
4. Mittel nach Anspruch 1, wobei der pharmazeutisch annehmbare Träger zusätzlich ein oder mehrere Mittel umfaßt, ausgewählt aus der Gruppe, bestehend aus Kohlenhydraten und modifizierten Kohlenhydraten und Derivaten davon, Polyethylen- und/oder Polypropylen glykol und Derivaten davon, anorganischen Füllstoffen oder Gleitmitteln, Fettsäuren und ihren Estern und Salzen, Konservierungsmitteln und Beschichtungsmitteln.
5. Mittel nach Anspruch 1, umfassend einen enteralen Überzug zur Freisetzung des Inhalts in dem oberen Teil des Dünndarms.
6. Mittel nach einem der vorangehenden Ansprüche, wobei der enterale Überzug ausgewählt ist aus Cellulose-Derivaten, umfassend Hydroxypropyl-methyl-cellulose-phthalat, Celluloseacetat-phthalat, Celluloseacetat-trimellitat und ähnlichen Derivaten von Cellulose und anderen Kohlenhydrat-Polymeren, Phthalaten von Vinylacetat und ähnlichen Teilstern von zweibasischen oder dreibasischen Carbonsäuren mit Polyvinylacetat und ähnlichen alkoholische Hydroxylgruppen enthaltenden Polymeren oder einem Gemisch davon.
7. Verfahren zur Herstellung einer Einzeldosis des Mittels nach einem der Ansprüche 1 bis 6, umfassend die folgenden Stufen:
  - Vermischen des Peptids mit einem geeigneten Träger, der ein Puffermittel enthält, das bei einem pH von 2 bis 6, vorzugsweise von pH 4 bis pH 5,5, insbesondere bei einem pH von etwa 5,1 puffert,
  - Späronisieren des Gemisches zur Bildung von Kügelchen mit einem Durchmesser von weniger als etwa 2 mm,
  - Überziehen der Kügelchen mit einem enteralen Überzug, der in Magensaft bei einem pH von etwa 5,0 oder darüber leicht löslich, aber bei einem wesentlich niedrigeren pH nicht leicht löslich ist,
  - Einfüllen der überzogenen Kügelchen in Kapseln oder Einbauen in Tabletten, wobei die Kapseln oder Tabletten im Magen leicht zerfallen.

### Revendications

1. Composition pharmaceutique sous Corne solide destinée à une administration orale, comprenant un peptide choisi parmi la vasopressine, l'oxytocine, ou un analogue de la vasopressine ou de l'oxytocine, un revêtement entérique facilement soluble dans le jus gastrique à un pH d'environ 6,5 ou moins, de préférence à environ 5,5, mais pas


# EP 0 752 877 B1

facilement soluble à un pH substantiellement inférieur à 5,0, ledit revêtement étant choisi parmi des polymères ayant des groupes carboxyle dissociables, et un transporteur pharmaceutiquement acceptable, contenant un agent de tamponnement, tamponnant à un pH de 2 à 6, à condition que la composition ne comprenne pas un inhibiteur de protéase.

2. Composition selon la revendication 1, dans laquelle le peptide est choisi dans le groupe constitué de DDAVP (desmopressine), de l'oxytocine, de CAP (atosiban) et de la carbetocine.
3. Composition selon la revendication 2, dans laquelle le peptide est DDAVP.
4. Composition selon la revendication 1, dans laquelle le transporteur pharmaceutiquement acceptable comprend, de plus, un ou plusieurs agents choisis dans le groupe constitué des glucides, glucides modifiés et leurs dérivés, du polyéthylène et/ou du polypropylène glycol et leurs dérivés, de charges inorganiques ou d'agents lubrifiants, d'acides gras et leurs esters et sels, de conservateurs et d'agents de revêtement.
5. Composition selon la revendication 1, comprenant un revêtement entérique pour libération de son contenu dans la partie supérieure de l'intestin grêle.
6. Composition selon l'une quelconque des revendications précédentes, dans laquelle le revêtement entérique est choisi parmi des dérivés de la cellulose, dont le phtalate d'hydroxypropylméthylcellulose, l'acétophthalate de cellulose, l'acétotrimellitate de cellulose et des dérivés similaires de la cellulose et d'autres polymères glucidiques, des phtalates d'acétate de vinyle et des esters partiels similaires d'acide carboxyliques dibasiques ou tribasiques avec de l'acétate de polyvinyle et similaire, des polymères portant des groupes hydroxyles alcooliques ou un mélange de tels polymères.
7. Procédé de fabrication de doses simples de la composition selon l'une des revendications 1 à 6, comprenant les étapes suivantes :
  - mélange du peptide et du transporteur approprié, comprenant un agent de tamponnement, tamponnant dans la plage de pH allant de pH 2 à pH 6, de plus grande préférence de pH 4 à pH 5,5, d'encore plus grande préférence à environ pH 5,
  - sphéronisation du mélange pour former des sphères d'un diamètre inférieur à environ 2 mm,
  - revêtement des sphères avec un revêtement entérique qui est facilement soluble dans le jus gastrique à pH 5,0 ou supérieur, mais pas facilement soluble à un pH sensiblement inférieur,
  - remplir les sphères revêtues dans des capsules ou les incorporer dans des comprimés, lesdites capsules ou lesdits comprimés pouvant se désintégrer facilement dans l'estomac.

EP 0 752 877 B1

*conc.*  
(pmol/ml)




DDAVP uptake in small intestine of male rats;  
0.9 % NaCl

*Fig. 2*



EP 0 752 877 B1

*conc.*  
(pmol/ml)



DDAVP uptake in small intestine of male rats;  
citrate buffer, pH 2.5 at start

*Fig. 1*

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**